Also: Bad and good results this earnings season, new tax rules, stock picks and how you too can be a mortgage lender
As part of the MarketWatch 50 series, Eleanor Laise interviewed Dr. Daniel Skovronsky, the chief scientific and medical officer at Eli Lilly & Co. LLY, +0.04%. The company’s stock has soared 63% this year amid excitement for its Mounjaro treatment for Type 2 diabetes. This is a GLP-1 medication, competing with Wegovy and Ozempic, which are made by Novo Nordisk A/S NVO, -0.32%. This category of medicine leads to such dramatic weight loss that it could affect a number of other industries.
Shares of Warner Bros. Discovery Inc. WBD, +2.28% plunged 19% on Wednesday after the company warned that it will not be able to pay down debt as quickly as it had planned if the TV advertising market doesn’t recover. Another factor that may have upset investors was a 700,000 decline in direct-to-consumer subscriptions.
WBD in its current form was created on April 8, 2022, when AT&T Inc. T, -0.58% divested WarnerMedia, which was merged with Discovery Inc. Here’s a chart for the combined company’s stock price since that date:Earnings season and IPO buyers’ remorse There was a long period during which low interest rates helped support many initial public offerings, with shares often soaring on the first day of trading.
Therese Poletti: Disney CEO Bob Iger is getting his hands dirty as he focuses on studio woes — will be it enough?New tax rules and advice for tax planning Andrew Kesher explains changes in tax brackets and rules for 2024:Stock picks When you see how people suffer from hurricanes or floods, you might wonder why anyone would choose to live in the affected areas. Michael Brush explains how to profit from peoples’ location preferences over the long term.
Eli Lilly Mounjaro Treatment Type 2 Diabetes GLP-1 Medication Weight Loss Novo Nordisk
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.The drug, which will be sold as Zepbound as an anti-obesity treatment, had previously been cleared by the FDA for the treatment of Type 2 diabetes
Read more »
Eli Lilly: still seeking UK approval on pen for weight-loss drugEli Lilly: still seeking UK approval on pen for weight-loss drug
Read more »
Eli Lilly’s new weight loss drug could drive down rivals' pricesThe Danish drugmaker’s Zepbound will undercut its rivals’ pricing by 21% but still cost over $1,000 a month.
Read more »
Eli Lilly, Novo Nordisk drop as UnitedHealth lowers Insulin costsEli Lilly, Novo Nordisk drop as UnitedHealth lowers Insulin costs
Read more »
FDA Approves Eli Lilly's Tirzepatide for Weight LossThe medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
Read more »
Eli Lilly Gets FDA Nod for Diabetes/Weight Loss DrugA new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.The U.S. Food and Drug Administration approved Eli Lilly's Zepbound, or tirzepatide.
Read more »